Loading...

CRNX CRINETICS PHARMACEUTICALS INC Product Launches 8-K Filing

CRNT

CRNX

CRINETICS PHARMACEUTICALS INC

(CRNX)

2025 8-K

Show Summary

Show Summary

Product Expansion

Financial Statements

Management Change

Financial Results

Management Change

Positive Study Results

Management Change

FDA Drug Approval

Financial Results

Management Change

New Drug Application

Management Change

Financial Results and CFO D...

Sales Agreement

Positive Findings from Deve...

Financial Results

Conference Presentation

Management Plan Approval

Phase 3 Study Results

Phase 2 Study Results

Securities Purchase Agreeme...

Financial Results

J.P. Morgan Healthcare Conf...

Positive Phase 2 Study Find...

Amendments to Bylaws

Financial Results

Underwriting Agreement

Phase 3 Study Results

Earnings Reports

Annual Meeting Results

Financial Results

Closure of Silicon Valley B...

Financial Results

J.P. Morgan Healthcare Conf...

External Links:

Crinetics Pharmaceuticals announced positive results from a Phase 2 study of atumelnant for treating congenital adrenal hyperplasia and plans to present more details in a conference call on January 10, 2025.

AI Assistant

CRINETICS PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.